Voyager Therapeutics has hit pause on a preclinical Alzheimer’s disease program just eight months after unveiling the asset. The neurology biotech announced back in July 2025 that it was adding a new ...

VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect ...

Voyager Technologies (NYSE:VOYG) earned a repeat ‘Outperform’ rating from Wedbush analysts after it reported strong fourth quarter results and outlined continued momentum heading into fiscal 2026. The ...

Voyager Technologies, Inc. (NYSE:VOYG) Q4 2025 Earnings Call Transcript March 10, 2026 Operator: Welcome to the Voyager Technologies, Inc. Fourth Quarter and Full Year 2025 Financial Results ...

Voyager Technologies, Inc. ( VOYG) Q4 2025 Earnings Call March 10, 2026 9:00 AM EDT ...

Moby Strategic Execution and Market Positioning. Performance in 2025 was driven by a 59% year-over-year increase in the ...

Voyager Technologies advances Starlab development through commercial agreements ; Starlab program reaches a major design ...

The Starlab commercial space station has fully booked its commercial payload space as it awaits the next phase of a NASA program.

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies ...

Voyager Technologies Inc VOYG shares are trading higher on Tuesday after the space and defense technology company posted fourth‑quarter results that featured a sizable adjusted EPS beat. Voyager ...

Breaking the AI Hardware Barrier: Enterprise-Grade Intelligence for Every Business—Starting with the MSPs Who Serve Them SMBs have the same intelligence needs as enterprises. They need clarity, speed, ...

Q4 2025 earnings call: record $266M backlog, higher 2026 revenue guide, defense growth and Starlab outlook—read now.